Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease

被引:31
|
作者
Nobbio, L
Vigo, T
Abbruzzese, M
Levi, G
Brancolini, C
Mantero, S
Grandis, M
Benedetti, L
Mancardi, G
Schenone, A
机构
[1] Univ Genoa, Dept Neurosci Ophthalmol & Genet, I-16132 Genoa, Italy
[2] Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy
[3] MNHN, CNRS, UMR8572, F-75005 Paris, France
[4] Univ Udine, Dept Biomed Sci & Technol, Biol Sect, I-33100 Udine, Italy
[5] Dulbecco Telethon Inst, CNR, ITB, I-20090 Segrate, Italy
关键词
CMTlA; hereditary neuropathy; PMP22; Schwann cell; axon; motility; migration; proliferation; myelin; dysmyelination;
D O I
10.1016/j.nbd.2004.02.007
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Charcot-Marie-Tooth type 1A (CMT1A) is a hereditary demyelinating neuropathy due to an increased genetic dosage of the peripheral myelin protein 22 (PMP22). The mechanisms leading from PMP22 overexpression to impairment of myelination are still unclear. We evaluated expression and processing of PMP22, viability, proliferation, migration, motility and shaping properties, and ability of forming myelin of PMP22 transgenic (PMP22(tg)) Schwann cells in culture. In basal conditions, PMP22(tg) Schwann cells, although expressing higher PMP22 levels than control ones, show normal motility, migration and shaping properties. Addition of forskolin to the media induces an additional stimulation of PMP22 expression and results in an impairment of cells migration and motility, and a reduction of cell area and perimeter. Similarly, co-culturing transgenic Schwann cells with neurons causes an altered cells differentiation and an impairment of myelin formation. In conclusion, exposure of PMP22tg Schwann to the axon or to axonal-mimicking stimuli significantly affects the transition of transgenic Schwann cells to the myelinating phenotype. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:263 / 273
页数:11
相关论文
共 50 条
  • [1] Ultrastructural distribution of PMP22 in Charcot-Marie-Tooth disease type 1A
    Haney, C
    Snipes, GJ
    Shooter, EM
    Suter, U
    Garcia, C
    Griffin, JW
    Trapp, BD
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1996, 55 (03): : 290 - 299
  • [2] Distal enhancers upstream of the Charcot-Marie-Tooth type 1A disease gene PMP22
    Jones, Erin A.
    Brewer, Megan H.
    Srinivasan, Rajini
    Krueger, Courtney
    Sun, Guannan
    Charney, Kira N.
    Keles, Sunduz
    Antonellis, Anthony
    Svaren, John
    HUMAN MOLECULAR GENETICS, 2012, 21 (07) : 1581 - 1591
  • [3] Squalenoyl siRNA PMP22 nanoparticles, a potent therapy for Charcot-Marie-Tooth disease type 1A
    Boutary, Suzan
    Massaad-Massade, Liliane
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 363 - 364
  • [4] SNP analysis of PMP22 and predicted PMP22 targeting mir genes in Charcot-Marie-Tooth neuropathy type 1A
    Nam, S. H.
    Lee, H. J.
    Shin, B. L.
    Choi, B. O.
    Chung, K. W.
    MOLECULAR BIOLOGY OF THE CELL, 2013, 24
  • [5] Severe phenotypes in a Charcot-Marie-Tooth 1A patient with PMP22 triplication
    Kim, Sung Min
    Lee, Jinho
    Yoon, Bo Ram
    Kim, Ye Jin
    Choi, Byung-Ok
    Chung, Ki Wha
    JOURNAL OF HUMAN GENETICS, 2015, 60 (02) : 103 - 106
  • [6] PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models
    Zhao, Hien Tran
    Damle, Sagar
    Ikeda-Lee, Karli
    Kuntz, Steven
    Li, Jian
    Mohan, Apoorva
    Kim, Aneeza
    Hung, Gene
    Scheideler, Mark A.
    Scherer, Steven S.
    Svaren, John
    Swayze, Eric E.
    Kordasiewicz, Holly B.
    JOURNAL OF CLINICAL INVESTIGATION, 2018, 128 (01): : 359 - 368
  • [7] A transgenic rat modet of Charcot-Marie-Tooth disease with increased PMP22 gene dosage
    Sereda, M
    Griffiths, IR
    Puhlhofer, A
    Magyar, JP
    Meink, HM
    Zimmermann, F
    Rossner, M
    Schneider, A
    Suter, U
    Nave, KA
    JOURNAL OF NEUROCHEMISTRY, 1996, 66 : S1 - S1
  • [8] AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells
    Yoshioka, Yuki
    Taniguchi, Juliana Bosso
    Homma, Hidenori
    Tamura, Takuya
    Fujita, Kyota
    Inotsume, Maiko
    Tagawa, Kazuhiko
    Misawa, Kazuharu
    Matsumoto, Naomichi
    Nakagawa, Masanori
    Inoue, Haruhisa
    Tanaka, Hikari
    Okazawa, Hitoshi
    COMMUNICATIONS MEDICINE, 2023, 3 (01):
  • [9] AAV-mediated editing of PMP22 rescues Charcot-Marie-Tooth disease type 1A features in patient-derived iPS Schwann cells
    Yuki Yoshioka
    Juliana Bosso Taniguchi
    Hidenori Homma
    Takuya Tamura
    Kyota Fujita
    Maiko Inotsume
    Kazuhiko Tagawa
    Kazuharu Misawa
    Naomichi Matsumoto
    Masanori Nakagawa
    Haruhisa Inoue
    Hikari Tanaka
    Hitoshi Okazawa
    Communications Medicine, 3
  • [10] Left ventricular hypertrabeculation/noncompaction with PMP22 duplication-based Charcot-Marie-Tooth disease type 1A
    Corrado, Giovanni
    Checcarelli, Nicoletta
    Santarone, Mauro
    Stoellberger, Claudia
    Finsterer, Josef
    CARDIOLOGY, 2006, 105 (03) : 142 - 145